跳至主要内容
临床试验/NCT00578240
NCT00578240
进行中(未招募)
不适用

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Memorial Sloan Kettering Cancer Center1 个研究点 分布在 1 个国家目标入组 5,290 人1990年4月1日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Prostate Cancer
发起方
Memorial Sloan Kettering Cancer Center
入组人数
5290
试验地点
1
状态
进行中(未招募)
最后更新
上个月

概览

简要总结

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

详细描述

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.

注册库
clinicaltrials.gov
开始日期
1990年4月1日
结束日期
2026年12月1日
最后更新
上个月
研究类型
Observational
性别
Male

研究者

入排标准

入选标准

  • Men with prostate conditions representing the following disease states:
  • No Cancer Diagnosis
  • Clinically Localized Disease
  • Rising PSA
  • Clinical Metastases: Noncastrate
  • Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
  • Signed informed consent

排除标准

  • Patients without any prostate related problems.

结局指标

主要结局

未指定

研究点 (1)

Loading locations...

相似试验